search
Back to results

Effect of Addition of Oral Montelukast to Standard Treatment in Acute Moderate to Severe Asthma in Children (Montelukast)

Primary Purpose

Bronchial Asthma

Status
Completed
Phase
Phase 3
Locations
India
Study Type
Interventional
Intervention
montelukast
Placebo
Sponsored by
All India Institute of Medical Sciences, New Delhi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bronchial Asthma focused on measuring Montelukast, Acute Asthma

Eligibility Criteria

5 Years - 15 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children aged 5-15 years of age, either sex seeking treatment with acute moderate to severe asthma in pediatric casualty/ chest clinic/ out patient services. Acute moderate to severe asthma is defined as modified pulmonary index score of more than 9.

Exclusion Criteria:

  • Children with life threatening asthma (poor respiratory efforts, cyanosis, altered sensorium).
  • Children who had received montelukast within one week of arrival.
  • Children with other chronic respiratory conditions (including congenital lung abnormalities) like tuberculosis, cystic fibrosis or other acute illnesses that would complicate current treatment and response for asthma.
  • Children with altered sensorium/unable to take oral medication.

Sites / Locations

  • All India Institute of Medical Sciences

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

A1

A2

Arm Description

Children Between 5-15 Years of Age Receiving Montelukast

Children Between 5-15 Years of Age Receiving Placebo

Outcomes

Primary Outcome Measures

Reduction in modified pulmonary index score (MPIS) to less than 9 at the end of 4 hours.

Secondary Outcome Measures

Change in FEV1 at the end of 4 hours
Adverse effects: Headache, nausea, vomiting, abdominal pain
Need for hospitalization

Full Information

First Posted
November 29, 2007
Last Updated
November 13, 2008
Sponsor
All India Institute of Medical Sciences, New Delhi
search

1. Study Identification

Unique Protocol Identification Number
NCT00565955
Brief Title
Effect of Addition of Oral Montelukast to Standard Treatment in Acute Moderate to Severe Asthma in Children
Acronym
Montelukast
Official Title
Effect Of Addition of Oral Montelukast to Standard Treatment in Acute Moderate to Severe Asthma in Children Between 5-15 Years of Age - A Randomized, Double Blind, Placebo Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2008
Overall Recruitment Status
Completed
Study Start Date
March 2007 (undefined)
Primary Completion Date
October 2008 (Actual)
Study Completion Date
October 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
All India Institute of Medical Sciences, New Delhi

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Available evidences show a role of oral montelukast in acute asthma. Safety of oral montelukast is well established in children, as evidenced by use of oral montelukast in long term management of asthma. Therefore, the investigators planned this study to see the effect of oral montelukast as add on therapy to standard treatment in acute moderate to severe asthma in children between 5-15 years of age. HYPOTHESIS: Addition of single dose of oral montelukast to standard therapy in acute moderate to severe asthma in children aged 5-15 years will reduce the modified pulmonary index score to less than 9 in 90% children compared to 70% in children receiving a placebo.
Detailed Description
Leukotrienes plays an important role as mediator for inflammatory changes in acute as well as chronic asthma. There are three randomized controlled trials involving 274 adult patients with acute asthma who were treated with montelukast (intravenous in 2 and intravenous and oral in one study) to see the beneficial response in spirometry. All the studies showed significant improvement in FEV1 in first 2 hours. These studies show that oral montelukast causes improved pulmonary function and has a rapid onset of action. However, these studies are carried out in adults. Safety of oral montelukast is well established in children, as evidenced by use of oral montelukast in long term management of asthma. Therefore, we planned this study to see the effect of oral montelukast as add on therapy to standard treatment in acute moderate to severe asthma in children between 5-15 years of age.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bronchial Asthma
Keywords
Montelukast, Acute Asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
116 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A1
Arm Type
Active Comparator
Arm Description
Children Between 5-15 Years of Age Receiving Montelukast
Arm Title
A2
Arm Type
Placebo Comparator
Arm Description
Children Between 5-15 Years of Age Receiving Placebo
Intervention Type
Drug
Intervention Name(s)
montelukast
Intervention Description
Standard case management will be carried out as per guidelines given by British Thoracic Society. All patients will receive montelukast or similar looking placebo tablets. The doses of montelukast will be as follows: 5-12 years: 5 mg chewable tablet of montelukast; > 12 years: 10 mg chewable tablet of montelukast. Study drug will be administered at time of administration of steroid.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
The patients will receive placebo tablets.
Primary Outcome Measure Information:
Title
Reduction in modified pulmonary index score (MPIS) to less than 9 at the end of 4 hours.
Time Frame
4 hours
Secondary Outcome Measure Information:
Title
Change in FEV1 at the end of 4 hours
Time Frame
4 hours
Title
Adverse effects: Headache, nausea, vomiting, abdominal pain
Time Frame
4 hours
Title
Need for hospitalization
Time Frame
4 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children aged 5-15 years of age, either sex seeking treatment with acute moderate to severe asthma in pediatric casualty/ chest clinic/ out patient services. Acute moderate to severe asthma is defined as modified pulmonary index score of more than 9. Exclusion Criteria: Children with life threatening asthma (poor respiratory efforts, cyanosis, altered sensorium). Children who had received montelukast within one week of arrival. Children with other chronic respiratory conditions (including congenital lung abnormalities) like tuberculosis, cystic fibrosis or other acute illnesses that would complicate current treatment and response for asthma. Children with altered sensorium/unable to take oral medication.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
SUSHIL K KABRA
Organizational Affiliation
All India Institute of Medical Sciences, New Delhi
Official's Role
Study Director
Facility Information:
Facility Name
All India Institute of Medical Sciences
City
New Delhi
State/Province
Delhi
Country
India

12. IPD Sharing Statement

Citations:
PubMed Identifier
20522464
Citation
Todi VK, Lodha R, Kabra SK. Effect of addition of single dose of oral montelukast to standard treatment in acute moderate to severe asthma in children between 5 and 15 years of age: a randomised, double-blind, placebo controlled trial. Arch Dis Child. 2010 Jul;95(7):540-3. doi: 10.1136/adc.2009.168567. Epub 2010 Jun 3.
Results Reference
derived

Learn more about this trial

Effect of Addition of Oral Montelukast to Standard Treatment in Acute Moderate to Severe Asthma in Children

We'll reach out to this number within 24 hrs